Alfred E. Slanetz
Founder at Geneius Biotechnology, Inc.
Alfred E. Slanetz active positions
| Companies | Position | Start | End |
|---|---|---|---|
Geneius Biotechnology, Inc.
 Geneius Biotechnology, Inc. Miscellaneous Commercial ServicesCommercial Services Geneius Biotechnology, Inc. operates as an immuno-oncology company. It develops autologous, adoptive T cell therapy technology which generates robust immune response to cancer. The company was founded by Alfred E. Slanetz in 2015 and is headquartered in Natick, MA. | Director/Board Member | 2014-12-31 | - |
| Chief Executive Officer | 2014-12-31 | - | |
| Founder | 2014-12-31 | - | |
| President | 2014-12-31 | - | |
Aim-Hi Accelerator Fund, Inc.
 Aim-Hi Accelerator Fund, Inc. Miscellaneous Commercial ServicesCommercial Services Aim-Hi Accelerator Fund, Inc. is a non-profit company that was born out of the National Foundation for Cancer Research (NFCR). The company is based in Rockville, MD. The company aims to bridge the gap between innovative, early-stage cancer research and successful development of high-impact oncology products. Aim-Hi is a new paradigm to fund translational research designed to focus on startups that have commercial potential at cancer therapeutic discovery. The company was founded by Sujuan Ba, Charlie Weatherspoon, Franklin Cary Salisbury. Sujuan Ba has been the CEO since incorporation. | Director/Board Member | - | - |
Career history of Alfred E. Slanetz
Former positions of Alfred E. Slanetz
| Companies | Position | Start | End |
|---|---|---|---|
| TRANSGENE | Corporate Officer/Principal | - | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - | - |
| BLUEBIRD BIO, INC. | President | 2006-12-31 | - |
Training of Alfred E. Slanetz
| Yale University | Doctorate Degree |
| Brown University | Graduate Degree |
| Hamilton College (New York) | Undergraduate Degree |
Statistics
International
| United States | 8 |
| France | 2 |
Operational
| President | 2 |
| Corporate Officer/Principal | 2 |
| Director/Board Member | 2 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 4 |
| Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| TRANSGENE | Health Technology |
| Private companies | 3 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Geneius Biotechnology, Inc.
Geneius Biotechnology, Inc. Miscellaneous Commercial ServicesCommercial Services Geneius Biotechnology, Inc. operates as an immuno-oncology company. It develops autologous, adoptive T cell therapy technology which generates robust immune response to cancer. The company was founded by Alfred E. Slanetz in 2015 and is headquartered in Natick, MA. | Commercial Services |
Aim-Hi Accelerator Fund, Inc.
Aim-Hi Accelerator Fund, Inc. Miscellaneous Commercial ServicesCommercial Services Aim-Hi Accelerator Fund, Inc. is a non-profit company that was born out of the National Foundation for Cancer Research (NFCR). The company is based in Rockville, MD. The company aims to bridge the gap between innovative, early-stage cancer research and successful development of high-impact oncology products. Aim-Hi is a new paradigm to fund translational research designed to focus on startups that have commercial potential at cancer therapeutic discovery. The company was founded by Sujuan Ba, Charlie Weatherspoon, Franklin Cary Salisbury. Sujuan Ba has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Alfred E. Slanetz
- Experience
